Related Experiment Video
Updated: Jun 3, 2025
05:51
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
3.6K
Rigidity in Parkinson's Disease: The Objective Effect of Levodopa
Marco Falletti1, Francesco Asci1, Alessandro Zampogna1,2
1Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
Summary
Levodopa effectively reduces parkinsonian rigidity by improving objective measures, particularly at higher movement speeds. This study quantifies levodopa's impact on the neural components of rigidity and long-latency reflexes in Parkinson's disease patients.
Area of Science:
- Neuroscience
- Biomedical Engineering
- Clinical Neurology
Background:
- Quantitative evidence for levodopa's effect on Parkinson's disease (PD) rigidity is limited.
- Recent studies highlight the velocity-dependent nature and neural basis of PD rigidity.
Purpose of the Study:
- To investigate the impact of levodopa on objective measures of rigidity in Parkinson's disease patients.
Main Methods:
- Eighteen PD patients underwent evaluations in both OFF and ON levodopa states.
- Rigidity was assessed clinically and instrumentally using robot-assisted wrist extensions across various angular velocities (5-280°/s).
- Surface electromyography measured short- and long-latency stretch reflexes (SLR and LLR).
Main Results:
- Levodopa improved clinical rigidity scores and reduced the neural component of force.
- Levodopa decreased the velocity dependence of LLRs but did not affect SLRs.
- Significant correlations were found between clinical improvements and biomechanical/neurophysiological changes.
Conclusions:
- Levodopa alleviates objective rigidity in PD by reducing its neural component and LLRs.
- The beneficial effects of levodopa on rigidity are more pronounced at higher angular velocities.
- These findings contribute to a new model of PD rigidity pathophysiology.
Related Concept Videos
01:24Parkinson's Disease: Treatment
215
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
215
01:15Parkinson's Disease: Overview
472
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
472
01:37Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
252
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
252
01:29Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
01:21Antipsychotic Drugs: Therapeutic Uses and Side Effects
119
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
119